Theseus Pharmaceuticals (THRX) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Theseus Pharmaceuticals has successfully completed its merger with Concentra Biosciences, after Concentra’s subsidiary acquired the majority of Theseus’s shares. Shareholders were offered $4.05 per share in cash, plus the opportunity for future payments through a contingent value right. The takeover resulted in Theseus becoming a wholly owned subsidiary of Concentra, leading to the delisting of Theseus’s shares from the Nasdaq and the termination of its Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. The transaction, which did not require a stockholder vote, signifies a significant shift in Theseus’s corporate structure and stock market presence.
For further insights into THRX stock, check out TipRanks’ Stock Analysis page.
